BrainCheck Selected for Pan-European Study with PREDICTOM
February 2025 — BrainCheck, a leader in digital cognitive health, has been selected to participate in the Pan-European PREDICTOM study, a groundbreaking initiative aimed at revolutionizing how we predict and intervene in neurodegenerative diseases, including dementia. This strategic collaboration will focus on combining digital, computerized, fluid, and neuroimaging biomarkers to create a comprehensive approach to identifying individual risk factors for cognitive decline.
PREDICTOM’s mission is to enable the adoption of precise, risk-reduction interventions for individuals at the right stage of disease, ensuring the maximum effect on preserving cognitive health. By incorporating a combination of biomarkers, the study seeks to provide a clear, personalized understanding of each participant’s risk and to direct them toward tailored interventions that can prevent further cognitive decline or the development of dementia.
A key component of this ambitious initiative is the use of a cost-effective, at-home or primary care-based biomarker collection process. This approach will allow healthcare practices to easily integrate biomarker data collection into routine care, ultimately empowering healthcare providers to identify individuals at high risk of dementia early on. The PREDICTOM platform will analyze this biomarker data using an open AI framework to generate personalized interventions that align with the specific needs of each participant.
At the conclusion of the study, the PREDICTOM consortium aims to produce comprehensive guidelines for the implementation of these cost-effective biomarkers in healthcare systems worldwide. This is expected to pave the way for a global shift toward more accessible and affordable cognitive healthcare solutions, allowing for the early detection and prevention of neurodegenerative conditions.
“We are thrilled to contribute our expertise in digital cognitive assessments to PREDICTOM,” said Chris Loughlin, CEO of BrainCheck. “This collaboration aligns with our mission to improve cognitive health and ensure that patients receive personalized care that can truly make a difference in their lives. By identifying individual risk factors early on and providing timely interventions, we believe this study will have a lasting impact on how cognitive decline is managed globally.”
BrainCheck’s involvement in PREDICTOM is a significant step forward in the company’s mission to improve early diagnosis and intervention for cognitive conditions. Through this collaboration, the consortium will not only further advance research but also make critical strides in developing a system that can be implemented in real-world healthcare settings to benefit patients everywhere.
Learn more about the PREDICTOM project on PREDICTOM’s official website, the PREDICTOM Project Factsheet, and follow them on LinkedIn for updates.
